NCT03792074

To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer

to Evaluate SCT510 Compared to Avasitin Respectively Combined Paclitaxel and Carboplatin First-line Treatment of Locally Advanced and Metastatic or Recurrent Squamous Cell Non-small Cell Lung Cancer Efficacy and Safety

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 560 (estimated)
• Sponsor: Sinocelltech Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety, efficacy and immunogenicity of SCT510 combined with paclitaxel and carboplatin compared with bevacizumab combined with paclitaxel and carboplatin in the first-line treatment of locally advanced metastatic or recurrent squamous cell non-small cell lung cancer.

Detailed description

A randomized, double-blind, parallel-controlled, multicenter phase 3 clinical trial. 560 patients with non-resectable locally advanced, metastatic or recurrent non-squamous cell non-small cell lung cancer (NSCLC) were randomly divided into two groups (SCT510 group and bevacizumab group) at a 1:1 ratio, and the treatment included combination chemotherapy and maintenance treatment, followed by follow-up.

Conditions

• Non-squamous Cell Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	SCT510	SCT510 Injection
DRUG	Bevacizumab	Bevacizumab Injection
DRUG	Paclitaxel	Paclitaxel Injection
DRUG	Carboplatin	Carboplatin injection

Timeline

• Start date: 2019-02-01
• Primary completion: 2021-05-01
• Completion: 2022-01-01
• First posted: 2019-01-03
• Last updated: 2019-01-03